Ann: Neuren completes enrolment in Pitt Hopkins Phase 2 trial, page-80

@giarc63 Thanks for sharing your research and thoughts.
I had a look at the video in @hottod post earlier today ... https://hotcopper.com.au/posts/71324020/single

It seems that there is a lot of global attention and research relating to a defect in the Shank 3 gene.



From @hottod 's post:
"And because it is caused by a defect in the Shank 3 gene, Phelan McDermid syndrome is of great interest to autism researchers."
This is discussed in the video.

Also, i refer to @Kryptonite 's post regarding video of the AGM: https://hotcopper.com.au/posts/71301739/single

During the AGM video Jon discusses that they did a lot more research of PMS and he talks to the results on these two slides:






So I think NEU purposely selected the PMS as the first trial as it sets the scene for the other NNZ-2591 trials.
So we need the results this week to come out positive IMHO.

If successful, then I think a lot of attention will focus down on NEU and NNZ-2591 for autism which has many different forms.

GLTA